Inbrain Neuroelectronics

INBRAIN Neuroelectronics is a health-tech company dedicated to developing the world's first intelligent graphene-neural platform. The company's flagship product is the Intelligent Network Modulation System, a groundbreaking device that harnesses the power of graphene to provide highly targeted and adaptive neuroelectronic therapy for treating Parkinson's disease.

Graphene, a two-dimensional lattice of carbon atoms arranged in a honeycomb pattern, is the thinnest and strongest material known to science. INBRAIN's neural platform leverages graphene's unique combination of electrical and mechanical properties to enable ultra-high signal resolution and decode therapy-specific biomarkers using machine learning algorithms. This allows for precise modulation of pathological neural networks, delivering personalized treatment.

The Intelligent Network Modulation System received Breakthrough Device Designation from the US Food and Drug Administration (FDA) in September 2023 as an adjunctive therapy for Parkinson's disease. This recognition expedites the regulatory process and facilitates the system's clinical translation. As of September 2023, INBRAIN reported no revenue figures.

In July 2021, INBRAIN secured a EUR 14.35 million Series A funding round, one of the largest in the Spanish medtech industry that year. The company was founded in 2020 as a spin-off from the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the Catalan Institution for Research and Advanced Studies (ICREA), with participation from the Institute of Microelectronics of Barcelona (IMB-CNM-CSIC).

INBRAIN acquired Innervia Bioelectronics, a subsidiary developing graphene-based systems for peripheral nerve applications, in collaboration with Merck KGaA. In January 2024, the company announced the GphT-BCI project with ICN2, aiming to revolutionize brain-computer interfaces through graphene transistors.